Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
April 29, 2002
- Mr Nordhoff Talks about Prospects of Gen-Probe
April 29, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 29, 2002
- PhRMA Japan Representative Discusses AIDS in Developing Countries
April 29, 2002
- BI to Introduce Int'l Strategic Products into Japan
April 29, 2002
- Aventis, Fujisawa Form Alliance for Marketing of Synercid Injection
April 29, 2002
- Korosho to Beef Up Measures to Ensure Medical Safety
April 29, 2002
- SSP Licenses Spelear to Han All Pharm in South Korea
April 29, 2002
- Medical Facilities Run by Profit-making Firms to Be Discussed Again
April 29, 2002
- Vital-Net, Ohmori Yakuhin Tohoku to Merge in July
April 29, 2002
- Tokai Univ. Initiates Drug Discovery Project
April 29, 2002
- Animal Study Contracts Increasing: Huntingdon Life Sciences
April 29, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
April 29, 2002
- BUSINESS NEWS IN BRIEF
April 29, 2002
- Tokyo Katei Yakko Proposes New Distribution for Home Remedies
April 29, 2002
- WEBSITE NEWS
April 29, 2002
- LIFE Corporation to Expand Health Food Product Line
April 29, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
April 29, 2002
- NPO to Be Inaugurated to Promote Self-medication
April 29, 2002
- Kusuri Proverbs Reveal Japanese Spirit (8)
April 29, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…